Among these, KRAS-G12D is the leading mutation in pancreatic (45%) and colorectal adenocarcinoma (45%), while KRAS-G12C mainly occurs in lung adenocarcinoma (46%) (Fig. 1c) [14]. This evidence concerns the gene KRAS and lung adenocarcinoma.